Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Osteochondroma 1Non-alcoholic Fatty Liver Disease 1Nevus, Epithelioid and Spindle Cell 1Lung Neoplasms 1Hematologic Neoplasms 1Giant Cell Tumors 1Fibrosis 1Endometrial Hyperplasia 1Carcinoma, Lobular 1Carcinoma in Situ 1Barrett Esophagus 1

Interventions

Flow Cytometry 36Gene Expression Profiling 34Surveys and Questionnaires 27Polymerase Chain Reaction 24Microarray Analysis 23Blood Specimen Collection 19Interviews as Topic 18Imatinib Mesylate 15Amplified Fragment Length Polymorphism Analysis 14Reverse Transcriptase Polymerase Chain Reaction 13Cytogenetic Analysis 13Rituximab 12venetoclax 11nilotinib 10Psychiatric Rehabilitation 10Dasatinib 10Immunologic Techniques 9DNA Methylation 9Blotting, Western 9ponatinib 8Observation 8In Situ Hybridization, Fluorescence 8Base Sequence 8Azacitidine 8ibrutinib 7fludarabine 7bosutinib 7Watchful Waiting 7Therapeutics 7Specimen Handling 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Sampling Studies × Other hematologic neoplasm × Clear all
NCT05463796 2025-08-07

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Dana-Farber Cancer Institute

Recruiting
5,000 enrolled
GastrointestinalGynecologicOther hematologic neoplasmThoracic

Barrett Esophagus, Carcinoma in Situ, Endometrial Hyperplasia, Fibrosis, Giant Cell Tumors, Lung Neoplasms, Osteochondroma, Carcinoma, Lobular, Nevus, Epithelioid and Spindle Cell, Hematologic Neoplasms, Non-alcoholic Fatty Liver Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡